Dianthus Therapeutics, Inc. (DNTH) Stock Price & Analysis
Dianthus Therapeutics, Inc. (DNTH) closed at USD 74.53 on Thursday, October 15, 2026, down 0.31% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 74.76; the Oct 15, 2026 session ranged USD 72.67–77.55 on volume of 943,572 shares. Market capitalization is $4.17B, with a 52-week range of USD 32.22–117.88 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/DNTH.md
Key facts (DNTH)
- 1 of 80 tracked superinvestors hold DNTH (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Analysts: Buy (mean 1.94 on a 1–5 scale) (17 analysts), mean target USD 140.8 (range 122–200).
- Total return with dividends: 1Y +107.0% vs S&P 500 +18.1%; 5Y -30.8% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD -0.95, revenue estimate $366K.
Superinvestors (SEC 13F-HR, Q2 2026) (DNTH)
1 of 80 tracked investors hold DNTH. Change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Polen Capital | Polen Capital Management | 0.01% | $910K | Added +126.6% |
Analysts (DNTH)
Consensus Buy (mean 1.94 on a 1–5 scale), 17 analysts; mean target USD 140.8 (low 122, high 200).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-15 | HC Wainwright & Co. | Reiterated | Buy | $158 |
| 2026-09-11 | JP Morgan | Initiated | Overweight | $135 |
| 2026-09-04 | Citigroup | Initiated | Buy | $156 |
| 2026-08-06 | Truist Securities | Target raised | Buy | $110 → $128 |
| 2026-08-06 | HC Wainwright & Co. | Target raised | Buy | $130 → $158 |
| 2026-08-05 | Wedbush | Target raised | Outperform | $105 → $122 |
| 2026-08-03 | Evercore ISI Group | Target raised | Outperform | $120 → $134 |
Total return (dividends reinvested) (DNTH)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | +107.0% | -30.8% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +107.5% | -7.1% |
| Volatility (annualized) | 59.4% | 90.8% |
| Max drawdown | -35.7% (Aug 2026→Oct 2026) | -95.4% (Nov 2021→Dec 2022) |
Key Statistics (as of October 16, 2026 at 05:22 UTC)
| Price | USD 74.53 |
|---|---|
| Change | ▼ 0.31% (down) |
| Previous Close | USD 74.76 |
| Open | USD 75.77 |
| Day Range | USD 72.67 – 77.55 |
| 52-Week Range | USD 32.22 – 117.88 |
| Volume | 943,572 shares |
| Market Cap | $4.17B |
| Exchange | NCM |
Technical Analysis (DNTH)
Nexqual's technical model rates DNTH "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:22 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 14.13 (oversold) |
| vs SMA50 | Below (USD 100.07) |
| MACD | -6.63 (negative) |
Analyst Ratings (DNTH)
Wall Street analysts rate DNTH "Buy" based on 17 analysts, with a mean price target of USD 140.8 (range USD 122–200), per Nexqual as of October 16, 2026 at 05:22 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 17 |
| Mean Target | USD 140.8 |
| High Target | USD 200 |
| Low Target | USD 122 |
| Buy / Hold / Sell | 17 / 0 / 0 |
Earnings (DNTH)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.95 |
| Revenue Estimate | $366,420 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.9 vs est -0.91 ▲ beat |
| 2026-03-31 | USD -0.85 vs est -1.1 ▲ beat |
| 2025-12-31 | USD -1.43 vs est -1.03 ▼ miss |
| 2025-09-30 | USD -0.97 vs est -0.9 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financials & Fundamentals (DNTH)
| Total Revenue | $1.90M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +294.30% |
| Gross Margin | +100.00% |
| Operating Margin | -8079.11% |
| Profit Margin | +0.00% |
| ROE | -26.06% |
| Debt / Equity | 0 |
| Current Ratio | 26.1 |
| Total Cash | $886.81M |
| Total Debt | $1.29M |
| Free Cash Flow (fiscal year ended Dec 2025, SEC 10-K) | -$129.27M (-6349.4% of revenue) |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Financial Health Score (DNTH)
Nexqual rates Dianthus Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:22 UTC.
| Growth | Critical — Revenue -67% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $887M cash vs $1M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$129M (FY ended Dec 2025, 10-K), burning cash |
| Efficiency | Critical — ROE -26%, ROA -17.7% |
Ownership (DNTH)
| Insider Ownership | +0.12% |
|---|---|
| Institutional Ownership | +127.87% |
| Shares Outstanding | 55.93M |
| Float | 55.85M |
| Short % of Float | +18.75% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Leadership (DNTH)
Dianthus Therapeutics, Inc. is led by Marino Garcia (age 59), President, CEO & Director, per Nexqual as of October 16, 2026 at 05:22 UTC.
| President, CEO & Director | Marino Garcia (age 59) |
|---|---|
| Executive VP, CFO, Chief Business Officer & Treasurer | Ryan Savitz (age 36) |
Major Backers & Investors (DNTH)
Notable institutional backers of Dianthus Therapeutics, Inc. include FMR, LLC, T. Rowe Price, Wellington Management, according to Nexqual as of October 16, 2026 at 05:22 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 14.96% |
| T. Rowe Price | 11.58% |
| Wellington Management | 5.89% |
| Fairmount Funds Management LLC | 4.63% |
| Price (T.Rowe) Associates Inc | 4.59% |
| Fidelity | 4.24% |
| Avidity Partners Management, LP | 3.84% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.73% |
| Vanguard Group | 9.69% |
| State Street | 6.82% |
Source: Nexqual, October 16, 2026 at 05:22 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt